Trial Profile
Study of evolution of treatment for HCV Genotype 3 (GT3) infected patients with advanced fibrosis/cirrhosis over time
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary) ; Velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 16 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018